Aprea Therapeutics (NASDAQ:APRE) Earns Buy Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE – Free Report) in a research report report published on Monday morning, Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock. Separately, Wedbush reiterated an outperform rating and set a $11.00 price target on shares of Aprea Therapeutics in […]
More Stories
Protagenic Therapeutics, Inc. Enters into Amendment No. 1 to At Market Issuance Sales Agreement
On January 9, 2025, Protagenic Therapeutics, Inc. announced that it has entered into Amendment No. 1 to the At Market...
Weather, Power, and Water Issues Persist in Los Angeles’ Eaton Fire Area
By Beige Luciano-Adams LOS ANGELES—Residents eager to return home and survey vast damage wrought by the Eaton Canyon Fire in...
Titanium Transportation Group (CVE:TTR) Share Price Passes Below 50 Day Moving Average – Should You Sell?
Titanium Transportation Group Inc. (CVE:TTR – Get Free Report)’s share price passed below its 50 day moving average during trading...
Invesco Aerospace & Defense ETF (NYSEARCA:PPA) Stock Price Passes Below 50-Day Moving Average – Here’s Why
Invesco Aerospace & Defense ETF (NYSEARCA:PPA – Get Free Report) shares crossed below its fifty day moving average during trading...
ImmuPharma (LON:IMM) Shares Up 4.9% – What’s Next?
ImmuPharma plc (LON:IMM – Get Free Report)’s share price shot up 4.9% during mid-day trading on Saturday . The company...
Omineca Mining and Metals (CVE:OMM) Stock Price Down 15.4% – Here’s Why
Omineca Mining and Metals Ltd. (CVE:OMM – Get Free Report)’s stock price traded down 15.4% on Saturday . The company...